Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer

The androgen receptor (AR) is widely expressed in breast cancer (BC) and evidence suggests dependence on AR signaling for growth and survival. AR antagonists such as enzalutamide and seviteronel have shown success in pre-clinical models and clinical trials of prostate cancer, and are currently being...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Cancer Ther
Hauptverfasser: Gordon, Michael A., D'Amato, Nicholas C., Gu, Haihua, Babbs, Beatrice, Wulfkuhle, Julia, Petricoin, Emanuel F., Gallagher, Isela, Dong, Ting, Torkko, Kathleen, Liu, Bolin, Elias, Anthony, Richer, Jennifer K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5517319/
https://ncbi.nlm.nih.gov/pubmed/28468774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0111
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge